Literature DB >> 18809447

Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.

Brice Barefoot1, Natalie J Thornburg, Daniel H Barouch, Jae-Sung Yu, Christopher Sample, Robert E Johnston, Hua Xin Liao, Thomas B Kepler, Barton F Haynes, Elizabeth Ramsburg.   

Abstract

The prevention of infectious disease via prophylactic immunization is a mainstay of global public health efforts. Vaccine design would be facilitated by a better understanding of the type and durability of immune responses generated by different vaccine vectors. We report here the results of a comparative immunogenicity trial of six different vaccine vectors expressing the same insert antigen, cowpox virus B5 (CPXV-B5). Of those vectors tested, recombinant adenovirus (rAd5) was the most immunogenic, inducing the highest titer anti-B5 antibodies and conferring protection from sublethal vaccinia virus challenge in mice after a single immunization. We tested select heterologous prime-boost combinations and identified recombinant vesicular stomatitis virus (rVSV) and recombinant Venezuelan equine encephalitis virus replicons (VRP) as the most synergistic regimen. Comparative data such as those presented here are critical to efforts to generate protective vaccines for emerging infectious diseases as well as for biothreat agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18809447      PMCID: PMC2646904          DOI: 10.1016/j.vaccine.2008.09.007

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

1.  Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice.

Authors:  K A Bernard; W B Klimstra; R E Johnston
Journal:  Virology       Date:  2000-10-10       Impact factor: 3.616

2.  Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.

Authors:  N L Davis; I J Caley; K W Brown; M R Betts; D M Irlbeck; K M McGrath; M J Connell; D C Montefiori; J A Frelinger; R Swanstrom; P R Johnson; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Protection of nonimmune volunteers against rubella by intravenous administration of normal human gamma globulin.

Authors:  R Martin du Pan; B Koechli; A Douath
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

4.  Data on the efficiency of specific antimumps immunoglobulins in the prevention of mumps and of its complications.

Authors:  Y Copelovici; D Strulovici; A L Cristea; V Tudor; V Armaşu
Journal:  Virologie       Date:  1979 Jul-Sep       Impact factor: 0.474

5.  Prevention or modification of varicella using zoster immune plasma.

Authors:  H H Balfour; K E Groth; J McCullough; J M Kalis; S C Marker; M E Nesbit; R L Simmons; J S Najarian
Journal:  Am J Dis Child       Date:  1977-06

6.  Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.

Authors:  Karl Haglund; Ingrid Leiner; Kristen Kerksiek; Linda Buonocore; Eric Pamer; John K Rose
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.

Authors:  David R Kaufman; Jaap Goudsmit; Lennart Holterman; Bonnie A Ewald; Matthew Denholtz; Colleen Devoy; Ayush Giri; Lauren E Grandpre; Jean-Michel Heraud; Genoveffa Franchini; Michael S Seaman; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

8.  Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.

Authors:  Elizabeth Ramsburg; Nina F Rose; Preston A Marx; Megan Mefford; Douglas F Nixon; Walter J Moretto; David Montefiori; Patricia Earl; Bernard Moss; John K Rose
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 9.  Neutralizing antiviral antibody responses.

Authors:  R M Zinkernagel; A LaMarre; A Ciurea; L Hunziker; A F Ochsenbein; K D McCoy; T Fehr; M F Bachmann; U Kalinke; H Hengartner
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

Review 10.  The challenge of emerging and re-emerging infectious diseases.

Authors:  David M Morens; Gregory K Folkers; Anthony S Fauci
Journal:  Nature       Date:  2004-07-08       Impact factor: 49.962

View more
  22 in total

1.  Increasing vaccine potency through exosome antigen targeting.

Authors:  Zachary C Hartman; Junping Wei; Oliver K Glass; Hongtao Guo; Gangjun Lei; Xiao-Yi Yang; Takuya Osada; Amy Hobeika; Alain Delcayre; Jean-Bernard Le Pecq; Michael A Morse; Timothy M Clay; Herbert K Lyerly
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

2.  Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Authors:  John B Schell; Nina F Rose; Kapil Bahl; Kathryn Diller; Linda Buonocore; Meredith Hunter; Preston A Marx; Ratish Gambhira; Haili Tang; David C Montefiori; Welkin E Johnson; John K Rose
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  Cowpox virus induces interleukin-10 both in vitro and in vivo.

Authors:  April H Spesock; Brice E Barefoot; Caroline A Ray; Daniel J Kenan; Michael D Gunn; Elizabeth A Ramsburg; David J Pickup
Journal:  Virology       Date:  2011-06-11       Impact factor: 3.616

4.  The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Authors:  Melissa A Cobleigh; Clinton Bradfield; Yuanjie Liu; Anand Mehta; Michael D Robek
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Co-expression of the C-terminal domain of Yersinia enterocolitica invasin enhances the efficacy of classical swine-fever-vectored vaccine based on human adenovirus.

Authors:  Helin Li; Pengbo Ning; Zhi Lin; Wulong Liang; Kai Kang; Lei He; Yanming Zhang
Journal:  J Biosci       Date:  2015-03       Impact factor: 1.826

6.  A quantitative comet infection assay for influenza virus.

Authors:  Stephen M Lindsay; Andrea Timm; John Yin
Journal:  J Virol Methods       Date:  2011-12-03       Impact factor: 2.014

7.  A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika.

Authors:  Jesse H Erasmus; Amit P Khandhar; Jeff Guderian; Brian Granger; Jacob Archer; Michelle Archer; Emily Gage; Jasmine Fuerte-Stone; Elise Larson; Susan Lin; Ryan Kramer; Rhea N Coler; Christopher B Fox; Dan T Stinchcomb; Steven G Reed; Neal Van Hoeven
Journal:  Mol Ther       Date:  2018-08-02       Impact factor: 11.454

8.  Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Authors:  Clement A Meseda; Anne E Mayer; Arunima Kumar; Alonzo D Garcia; Joseph Campbell; Paul Listrani; Jody Manischewitz; Lisa R King; Hana Golding; Michael Merchlinsky; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

9.  Qualitative and quantitative analysis of adenovirus type 5 vector-induced memory CD8 T cells: not as bad as their reputation.

Authors:  Maria Abildgaard Steffensen; Peter Johannes Holst; Sanne Skovvang Steengaard; Benjamin Anderschou Holbech Jensen; Christina Bartholdy; Anette Stryhn; Jan Pravsgaard Christensen; Allan Randrup Thomsen
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

Review 10.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.